| Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). | |
| | |
MedLine Citation:
|
PMID: 2501516 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
With data from 2 large randomized British Medical Research Council studies we identified several factors influencing the recurrence of newly diagnosed superficial bladder cancer. Using multivariate methods to assess the relative importance of these factors we found the most important to be the result of cystoscopy performed 3 months after initial transurethral resection and the number of tumors (single or multiple) at presentation. With these 2 factors we divided the patient population into 3 groups with varying degrees of prognosis. Different followup procedures are proposed for each of these 3 groups. |
| | |
Authors:
|
M K Parmar; L S Freedman; T B Hargreave; D A Tolley |
Related Documents
:
|
12113086 - Retinoids in the prevention of bladder cancer. 21960356 - Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created f... 12184646 - Arsenic keratosis and pigmentation accompanied by multiple bowen's disease and genitour... 22212706 - Psychological aspects of prostate cancer: a clinical review. 16737666 - Can manual treatment of lymphedema promote metastasis? 21995576 - Chronic inflammation and immunologic-based constraints in malignant disease. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: The Journal of urology Volume: 142 ISSN: 0022-5347 ISO Abbreviation: J. Urol. Publication Date: 1989 Aug |
Date Detail:
|
Created Date: 1989-08-25 Completed Date: 1989-08-25 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0376374 Medline TA: J Urol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 284-8 Citation Subset: AIM; IM |
Affiliation:
|
MRC Cancer Trials Office, Cambridge, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intravesical Carcinoma, Transitional Cell / drug therapy, mortality* Cystoscopy* Follow-Up Studies Humans Mitomycin Mitomycins / therapeutic use Multicenter Studies as Topic Neoplasm Recurrence, Local* Prognosis Statistics as Topic Thiotepa / therapeutic use Time Factors Urinary Bladder Neoplasms / drug therapy, mortality* |
| Chemical | |
Reg. No./Substance:
|
0/Mitomycins; 50-07-7/Mitomycin; 52-24-4/Thiotepa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: In vitro processing of dengue virus structural proteins: cleavage of the pre-membrane protein.
Next Document: The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in...